Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience
American Journal of Hematology · 2026-07 · 101 (7) · 1597-1604
DOI: 10.1002/ajh.70307 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 16.04.2026. Verfasst von Bruno Fattizzo und 38 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a cohort of 57 CAD patients (median age 73.5 years, 56% females). At baseline, patients had severe to moderate anemia (median Hb 8.9 g/dL) and active hemolysis, with a substantial transfusion burden despite a median of 2 prior therapies, including corticosteroids and rituximab. After sutimlimab initiation, median Hb increased by 2 g/dL within 2 weeks and reached 12 g/dL in 4 weeks, remaining stable up to 24 months. This improvement was paralleled by an early and durable normalization of hemolytic markers. Objective responses were observed in most patients by week 2, with complete responses in approximately 50% by Week 4 and 55%–60% during long‐term follow‐up. Peripheral cold‐induced symptoms did not improve and were associated with reduced response rates. Inadequate reticulocytosis also predicted poorer response and suggests the combination with recombinant erythropoietin. Sutimlimab was generally well tolerated. Infections were the most frequent adverse events (23%); severe infections predominantly occurred in previously rituximab‐treated individuals. Hemolytic exacerbations occurred in 16% of cases, mostly due to infections. Thrombotic complications were rare. Overall, sutimlimab demonstrated rapid, durable effectiveness and a favorable safety profile in heavily pretreated real‐world CAD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Department of Hematology, Saitama Medical University, Saitama, Japan.
- Departement of Internal Medicine and Clinical Immunology, National Reference Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Cré…
- Hematology and Bone Marrow Transplant Unit, Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy.
- Medizinische Abteilung Zentrum für Hämatologie Und Onkologie Leiter der Blutbank Apherese-Einheit, Hanusch-Krankenhaus der ÖGK, Wien, Austria.
ORCID-Profile: Bruno Fattizzo, Nilla Maschio, Dorela Lame, Uros Markovic, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Fabrizio Vianello, Catherine Broome, Bernd Jilma
Förderung
- Ministero della Salute
Zitieren
APA
Fattizzo, B., Sambruna, E., Miyakawa, Y., Michel, M., Visco, C., Fillitz, M., Kannourakis, G., Greve, M. B., Kleemiss, M., Cid, J., Patriarca, A., Pavan, L., Dizdari, A., Maschio, N., Sau, A., Bitetti, C., Colombo, R. M., Curreli, L., Lame, D., …, & Barcellini, W. (2026). Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience. American Journal of Hematology, 101(7), 1597-1604. https://doi.org/10.1002/ajh.70307
Vancouver
Fattizzo B, Sambruna E, Miyakawa Y, Michel M, Visco C, Fillitz M, et al. Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience. American Journal of Hematology. 2026;101(7):1597-1604. doi:10.1002/ajh.70307
BibTeX
@article{Fattizzo2026,
author = {Fattizzo, Bruno and Sambruna, Elisa and Miyakawa, Yoshitaka and Michel, Marc and Visco, Carlo and Fillitz, Michael and Kannourakis, George and Greve, Maria Bruna and Kleemiss, Moritz and Cid, Johan and Patriarca, Andrea and Pavan, Laura and Dizdari, Arbana and Maschio, Nilla and Sau, Antonella and Bitetti, Cinzia and Colombo, Riccardo Mario and Curreli, Luigi and Lame, Dorela and Markovic, Uros and Pappagallo, Fabrizio and Pedone, Giacinto Luca and Rapezzi, Davide and Sammartano, Vincenzo and Tumedei, Nicola and Solimando, Antonio Giovanni and Marit, Jalink and Fianchi, Luana and Khwaja, Jahanzaib and De Vivo, Antonio and Lanza, Francesco and Vianello, Fabrizio and Oliva, Esther N and Broome, Catherine and Passamonti, Francesco and Jaeger, Ulrich and Jilma, Bernd and Moulis, Guillaume and Barcellini, Wilma},
title = {Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {7},
pages = {1597--1604},
doi = {10.1002/ajh.70307}
}
EUVIMED